중앙백신
Financials
Valuation Metrics
중앙백신's Market Cap is ₩854B. At end of 2025 it was ₩907B. Ranked #1347 of 2,436 in KR market (top 55%), #747 of 1,649 on KOSDAQ (top 45%), #146 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 85.44B KRW | KR#1,347/2,436 Sec#146/234 |
| Revenue | 48.42B KRW | KR#1,799/2,436 Sec#124/234 |
| Net Income | 7.38B KRW | KR#993/2,436 Sec#64/234 |
| Total Assets | 124.42B KRW | KR#1,597/2,436 Sec#129/234 |
| Net Assets | 106.81B KRW | KR#1,350/2,436 Sec#110/234 |
| Employees | 187 | KR#1,140/2,436 Sec#95/234 |
| Value | ||
| P/E | 11.58x | KR#799/2,436 Sec#47/234 |
| P/B | 0.80x | KR#1,284/2,436 Sec#76/234 |
| PEG | 0.20x | KR#525/2,436 Sec#28/234 |
| P/S | 1.76x | KR#1,758/2,436 Sec#100/234 |
| EV/EBITDA | 11.03x | KR#663/2,436 Sec#33/234 |
| FCF Yield | 2.29% | KR#1,047/2,436 Sec#70/234 |
| Profitability | ||
| ROE | 6.91% | KR#803/2,436 Sec#59/234 |
| ROA | 5.93% | KR#536/2,436 Sec#41/234 |
| Op. Margin | 14.85% | KR#284/2,436 Sec#25/234 |
| Revenue Growth | -4.90% | KR#1,700/2,436 Sec#157/234 |
| Earnings Growth | 57.65% | KR#533/2,436 Sec#28/234 |
| Financial Health | ||
| Debt Ratio | 116.48% | KR#577/2,436 Sec#74/234 |
| Total Debt | 6.17B KRW | KR#1,741/2,436 Sec#166/234 |
| FCF | 1.95B KRW | KR#1,084/2,436 Sec#78/234 |
| Cash | 12.35B KRW | KR#1,544/2,436 Sec#117/234 |
| Current Ratio | 4.38x | KR#360/2,436 Sec#66/234 |
| Net Debt/EBITDA | -0.86x | KR#494/2,436 Sec#28/234 |
| Dividend | ||
| Div. Yield | 2.17% | KR#830/2,436 Sec#43/234 |
| Div. Growth | 17.65% | KR#464/2,436 Sec#25/234 |
| Performance | ||
| 1Y Return | -6.77% | KR#870/2,436 Sec#66/234 |
| 1M Return | -4.45% | KR#1,349/2,436 Sec#138/234 |
| From 52W High | -10.82% | KR#53/2,436 Sec#1/234 |
| 1Y MDD | -13.92% | KR#10/2,436 Sec#1/234 |
| Trading | ||
| Volume | 6,279 shares | KR#2,225/2,436 Sec#220/234 |
| Foreign Own. | 3.13% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 768 KRW | KR#736/2,436 Sec#53/234 |
| BPS | 11,539 KRW | KR#850/2,436 Sec#61/234 |
Company Info
Joongang Vaccine was established in 1968 as a private enterprise, converted to a corporation in 1994, and listed on KOSDAQ in 2003. Headquartered in Yuseong-gu, Daejeon, it manufactures about 80 types of animal vaccines for disease prevention, selling them to farms, distributors, and animal hospitals, and provides feed additive sales, rabies testing, disease diagnosis, and research services for biological products. With strengthened antibiotic regulations, the focus is shifting from treatment to prevention, increasing demand for animal vaccines, and the company is developing new markets in Southeast Asia, South America, and China.